Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Management of treatment-emergent peripheral neuropathy in multiple myeloma.

Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P.

Leukemia. 2012 Apr;26(4):595-608. doi: 10.1038/leu.2011.346. Epub 2011 Dec 23. Review.

PMID:
22193964
2.

Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.

El-Cheikh J, Stoppa AM, Bouabdallah R, de Lavallade H, Coso D, de Collela JM, Auran-Schleinitz T, Gastaut JA, Blaise D, Mohty M.

Clin Lymphoma Myeloma. 2008 Jun;8(3):146-52. doi: 10.3816/CLM.2008.n.017.

PMID:
18650177
3.

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.

Corso A, Mangiacavalli S, Varettoni M, Pascutto C, Zappasodi P, Lazzarino M.

Leuk Res. 2010 Apr;34(4):471-4. doi: 10.1016/j.leukres.2009.07.022. Epub 2009 Aug 11.

PMID:
19674790
4.

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J.

Br J Haematol. 2009 Mar;144(6):895-903. doi: 10.1111/j.1365-2141.2008.07573.x. Epub 2009 Jan 16.

PMID:
19170677
5.
6.

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.

Cancer. 2007 Sep 1;110(5):1042-9. Review.

7.

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.

Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M.

Haematologica. 2010 Feb;95(2):311-9. doi: 10.3324/haematol.2009.012674. Review.

8.

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.

Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K.

J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S4-S12. Erratum in: J Natl Compr Canc Netw. 2010 Mar;8(3):xlv. Dosage error in article text.

PMID:
20141673
9.

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.

Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I.

J Peripher Nerv Syst. 2008 Dec;13(4):275-82. doi: 10.1111/j.1529-8027.2008.00193.x.

10.

Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.

Koeppen S.

Oncol Res Treat. 2014;37(9):506-13. doi: 10.1159/000365534. Epub 2014 Aug 14. Review.

PMID:
25231692
11.

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.

Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, Palumbo A, Van Damme P, San-Miguel JF, Sonneveld P.

Lancet Oncol. 2010 Nov;11(11):1086-95. doi: 10.1016/S1470-2045(10)70068-1. Review.

PMID:
20932799
12.

Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.

Tacchetti P, Terragna C, Galli M, Zamagni E, Petrucci MT, Pezzi A, Montefusco V, Martello M, Tosi P, Baldini L, Peccatori J, Ruggieri M, Pantani L, Lazzaro A, Elice F, Rocchi S, Gozzetti A, Cavaletti G, Palumbo A, Cavo M.

Am J Hematol. 2014 Dec;89(12):1085-91. doi: 10.1002/ajh.23835. Epub 2014 Sep 17.

13.

General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.

Broyl A, Jongen JL, Sonneveld P.

Semin Hematol. 2012 Jul;49(3):249-57. doi: 10.1053/j.seminhematol.2012.04.001. Review.

PMID:
22726548
14.

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.

Cavaletti G, Jakubowiak AJ.

Leuk Lymphoma. 2010 Jul;51(7):1178-87. doi: 10.3109/10428194.2010.483303. Review.

PMID:
20497001
15.

Treatment-related symptom management in patients with multiple myeloma: a review.

Colson K.

Support Care Cancer. 2015 May;23(5):1431-45. doi: 10.1007/s00520-014-2552-1. Epub 2015 Feb 3. Review.

PMID:
25646616
16.

Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?

Palumbo A, Mateos MV, Bringhen S, San Miguel JF.

Blood Rev. 2011 Jul;25(4):181-91. doi: 10.1016/j.blre.2011.03.005. Epub 2011 Apr 16. Review.

PMID:
21497966
17.

Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.

Zaroulis CK, Chairopoulos K, Sachanas SP, Maltezas D, Tzenou T, Pessach I, Koulieris E, Koutra E, Kilindireas K, Pangalis GA, Kyrtsonis MC.

Leuk Lymphoma. 2014 Oct;55(10):2277-83. doi: 10.3109/10428194.2013.873535. Epub 2014 Mar 19.

PMID:
24552516
18.

Management of treatment-related adverse events in patients with multiple myeloma.

Mateos MV.

Cancer Treat Rev. 2010 May;36 Suppl 2:S24-32. doi: 10.1016/S0305-7372(10)70009-8. Review.

PMID:
20472185
19.

Therapy-related peripheral neuropathy in multiple myeloma patients.

Morawska M, Grzasko N, Kostyra M, Wojciechowicz J, Hus M.

Hematol Oncol. 2015 Dec;33(4):113-9. doi: 10.1002/hon.2149. Epub 2014 Nov 14. Review. Erratum in: Hematol Oncol. 2016 Jun;34(2):117.

PMID:
25399783
20.

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA.

J Clin Oncol. 2006 Jul 1;24(19):3113-20. Epub 2006 Jun 5.

PMID:
16754936

Supplemental Content

Support Center